ROIV

Roivant Sciences
D

ROIV

Arincen25/100B
40.640
USD
-0.02
(-0.05%)
Market Open
Last updated: · Delayed 15 min
Q2 FY2027 results
EPS-0.27+26.4%Revenue35.12M+710.0%
OverviewFinancialsForecastEarningsCompany

Roivant Sciences executives and insider trading

Eric Venker sold 2,875,000 shares for 87.35M USD in 18 sales over the last twelve months, the last on 3 November 2026, and bought none on the open market.

Over the last twelve months Roivant Sciences's insiders sold 32,405,462 shares for 828.85M USD in 111 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
111
Shares sold
32,405,462
Value sold
828.85M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
7.26M USD
0
1 month
21.60M USD
0
3 months
74.44M USD
0
6 months
217.94M USD
0
1 year
828.85M USD
49.96K USD
2 years
995.81M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Eric Venker CEOPresident & Chief Executive Officer of Immunovant392,875,00087.35M USD—3 Nov 2026—
Matthew Gline CEOChief Executive Officer & Director422,029,77446.17M USD—16 Apr 2026—
Keith S Manchester Director—5,858,561154.47M USD—30 Jun 2026—
Daniel Allen Gold Director—5,658,561147.38M USD—30 Jun 2026—
Vivek Ramaswamy 10 percent owner—4,958,348105.88M USD—15 Dec 2025—
Financial Lp Qvt Other: Director by Deputization—4,220,39898.03M USD—13 Feb 2026—
Mayukh Sukhatme President, Chief Investment Officer & Director503,197,14092.09M USD—21 Aug 2026—
Frank Torti President & Vant Chair473,000,00082.04M USD—23 Feb 2026—
Richard Pulik Chief Financial Officer46406,7319.12M USD—23 Dec 2025—
Meghan Fitzgerald Director—105,1123.27M USD—15 Sept 2026—
Melissa B, Epperly Director—82,2992.65M USD—1 Oct 2026—
Jennifer Humes Chief Accounting Officer4513,538384.07K USD—8 Apr 2026—

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
3 Nov 2026Eric VenkerSale200,00036.317.26M USD999,154Form 4
28 Oct 2026Eric VenkerSale200,00036.597.32M USD1,199,154Form 4
20 Oct 2026Eric VenkerSale185,85635.096.52M USD1,413,298Form 4
20 Oct 2026Eric VenkerSale14,14435.42500.98K USD1,399,154Form 4
1 Oct 2026Melissa B, EpperlySale16,85036.08607.95K USD15,854Form 4
1 Oct 2026Melissa B, EpperlySale90036.5732.91K USD14,954Form 4
30 Sept 2026Eric VenkerSale200,00036.627.32M USD1,599,154Form 4
15 Sept 2026Melissa B, EpperlySale4,33839.65172.00K USD10,500Form 4
15 Sept 2026Melissa B, EpperlySale60040.3824.23K USD9,900Form 4
15 Sept 2026Meghan FitzgeraldSale4,71239.68186.97K USD36,508Form 4
15 Sept 2026Meghan FitzgeraldSale40040.4516.18K USD36,108Form 4
8 Sept 2026Meghan FitzgeraldSale20,00039.90798.00K USD42,963Form 4
28 Aug 2026Eric VenkerSale166,18235.635.92M USD1,632,972Form 4
28 Aug 2026Eric VenkerSale33,81836.441.23M USD1,599,154Form 4
21 Aug 2026Mayukh SukhatmeSale144,75636.485.28M USD18,630,739Form 4

Common questions about Roivant Sciences's executives and insiders

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.